The FDA approved Tysabri in November 2024 to treat multiple sclerosis, and the drug has recorded significant sales for Biogen since then.
SMC approves Biogen's Vumerity for patients with multiple sclerosis treatment for adults with relapsing-remitting multiple sclerosis (RRMS).
Multiple sclerosis drug sales slump Biogen's fourth-quarter revenue from multiple sclerosis products fell 8% to $1.17 billion as some of the
Biogen and Alkermes won approval Oct. 30 for their new multiple sclerosis drug, Vumerity, according to The Boston Globe.
Biogen Stock Is Slipping Because a Multiple Sclerosis Drug Has Fierce Competition Biogen stock was slipping on Friday morning as one analyst
Biogen Stock Is Slipping Because a Multiple Sclerosis Drug Has Fierce Competition Biogen stock was slipping on Friday morning as one analyst
Biogen Inc. (NASDAQ:BIIB) signed an outcomes-based contract with PBM Prime Therapeutics LLC for Biogen's multiple sclerosis drugs under
Biogen (formerly Biogen Idec) for the oral treatment of multiple. Biogen terminates a phase III in Multiple sclerosis (In
F.D.A. Approves a Biogen Drug for Treating Multiple Sclerosis Biogen Inc. said yesterday that it had received approval from the Food and Drug Administration
Comments
A-fucking-mazing.